CorMedix initiated with a Buy at D. Boral Capital

D. Boral Capital initiated coverage of CorMedix (CRMD) with a Buy rating and $15 price target CorMedix is at the forefront of infection prevention in dialysis and critical care, with its flagship product, DefenCath, the analyst tells investors in a research note. The firm sees a “compelling value proposition” in mitigating catheter-related bloodstream infections initially in the multi-billion-dollar dialysis market.